MediciNova, Inc.
4350 La Jolla Village Drive, Suite 950
San Diego
California
92122
United States
Tel: 858-373-1500
Fax: 858-373-7000
Website: http://www.medicinova.com/
Email: info@medicinova.com
334 articles about MediciNova, Inc.
-
MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome
4/13/2022
MediciNova, Inc. announced that the Phase 2 clinical trial of MN-166 in hospitalized COVID-19 patients at risk for developing acute respiratory distress syndrome has completed enrollment.
-
MediciNova Announces Plans for a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia
4/11/2022
MediciNova, Inc. announced that the U.S. Food and Drug Administration has completed its review of a Phase 2 clinical trial protocol to evaluate MN-001 for the treatment of patients with non-alcoholic fatty liver disease, type 2 diabetes mellitus, and hypertriglyceridemia.
-
MediciNova Announces Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Alcoholism: Clinical and Experimental Research
4/7/2022
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that a secondary analysis of a Phase 2 clinical trial of MN-166 (ibudilast) in alcohol use disorder (AUD) was published in the journal Alcoholism: Clinical and Experimental Research.
-
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Korea
3/17/2022
MediciNova, Inc. announced that it has received a Notice of Allowance from the Korean Intellectual Property Office which covers MN-001 and MN-002 for the treatment of advanced nonalcoholic steatohepatitis.
-
MediciNova to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest
3/15/2022
MediciNova, Inc. announced that Geoffrey O'Brien, JD/MBA, Vice President and Executive Officer, will present a corporate overview at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28 – 30, 2022 from 9:00 a.m. - 5:00 p.m. EDT.
-
MediciNova Announces MN-166 (ibudilast) Identified as Potential Beneficial Pharmacotherapy for Treatment of Degenerative Cervical Myelopathy in Global Spine Journal
2/28/2022
MediciNova, Inc. and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MN-166 (ibudilast) was discussed as a potential beneficial pharmacological agent for the treatment of degenerative cervical myelopathy (DCM) in Global Spine Journal.
-
MediciNova Announces MN-166 (ibudilast) Identified as Promising Pharmacotherapy for Alcohol Use Disorder in Drugs
2/22/2022
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced MN-166 (ibudilast) was discussed as one of the promising pharmacological agents for the treatment of alcohol use disorder (AUD) in the journal Drugs.
-
MediciNova Receives a New Patent Covering MN-001 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Korea
2/1/2022
MediciNova, Inc. announced that it has received a new patent from the Korean Intellectual Property Office which covers MN-001 for the treatment of hypertriglyceridemia, hypercholesterolemia, and hyperlipoproteinemia.
-
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for Hepatic Ballooning in Canada
1/31/2022
MediciNova, Inc., today announced that it has received a Notice of Allowance from the Canadian Intellectual Property Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for hepatic ballooning.
-
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Alcohol Use Disorder in Europe
1/27/2022
MediciNova, Inc. today announced that it has received a Notice of Intention to Grant from the European Patent Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of alcohol use disorder.
-
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for Hepatic Ballooning in Europe
1/26/2022
MediciNova, Inc. and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Intention to Grant from the European Patent Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for hepatic ballooning.
-
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of ALS
12/13/2021
MediciNova, Inc. today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers the combination of MN-166 (ibudilast) and riluzole for the treatment of amyotrophic lateral sclerosis (ALS).
-
MediciNova Announces MN-166 (ibudilast) Poster Presentation at the 32nd International Symposium on ALS/MND
12/10/2021
MediciNova, Inc. and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Dr. Malath Makhay, Director, Scientific Affairs, presented the poster of MediciNova’s ongoing Phase 2b/3 clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS) at the 32nd International Symposium on ALS/MND.
-
MediciNova Announces New Data regarding MN-166 (ibudilast) in Glioblastoma Presented at the 26th Annual Meeting of the Society for Neuro-Oncology
11/22/2021
MediciNova, Inc. announced that MediciNova’s research collaborator, Justin Lathia PhD, Co-Director of the Brain Tumor Research and Therapeutic Development Center of Excellence at Cleveland Clinic Lerner Research Institute presented new data regarding MN-166 from a glioblastoma animal model study at the 26th Annual Meeting of the Society for Neuro-Oncology held November 18 - 21, 2021 in Boston.
-
MediciNova Announces New Data regarding MN-166 (ibudilast) in Uveal Melanoma Presented at the CURE OM Global Science Meeting
11/10/2021
MediciNova, Inc. announced that Grazia Ambrosini, PhD, an associate research scientist at Columbia University Vagelos College of Physicians and Surgeons, presented data regarding MN-166 in a uveal melanoma model study at the 10th Annual CURE OM Global Science Meeting held online as a part of the Society for Melanoma Research International Congress on October 28, 2021.
-
MediciNova Announces New Data regarding MN-166 (ibudilast) in Glioblastoma to be Presented at the Annual Meeting of the Society for Neuro-Oncology
11/3/2021
MediciNova, Inc., today announced that MediciNova’s collaborator, Dr. Justin Lathia, Co-Director of the Brain Tumor Research and Therapeutic Development Center of Excellence at Cleveland Clinic Lerner Research Institute, and Professor, Department of Molecular Medicine at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.
-
MediciNova Announces Abstract regarding the Mechanism by which MN-001 (tipelukast) Alters Triglyceride Metabolism Accepted for Presentation at the 19th International Symposium on Atherosclerosis (ISA2021)
10/21/2021
MediciNova, Inc. announced an abstract entitled “MN-001 reduces triglycerides levels in hepatocytes by down-regulating fatty acid translocase/CD36 expression" has been selected for presentation at the 19th International Symposium on Atherosclerosis to be held October 24 - 27, 2021 in a hybrid format both online and onsite at the Kyoto International Conference Center in Kyoto, Japan.
-
MediciNova to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
9/3/2021
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, announced that MediciNova will participate in the virtual Morgan Stanley 19th Annual Global Healthcare Conference which will be held from September 9 - 15, 2021.
-
MediciNova Announces MN-001 (tipelukast) Abstract regarding Lipid Metabolism in NASH/NAFLD Accepted for Presentation at The Liver Meeting® 2021, the Annual Meeting of the American Association for the Study of Liver Diseases
9/1/2021
MediciNova, Inc. announced an abstract entitled “Improvement of Intracellular Lipid Metabolism by Tipelukast in the Pathogenesis of NASH/NAFLD" has been selected for poster presentation at The Liver Meeting® 2021, the annual meeting of the American Association for the Study of Liver Diseases to be held November 12 - 15, 2021.
-
MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 32nd International Symposium on ALS/MND
8/30/2021
ediciNova, Inc. announced that an abstract regarding MediciNova’s ongoing Phase 2b/3 clinical trial of MN-166 in amyotrophic lateral sclerosis has been accepted for presentation at the 32nd International Symposium on ALS/MND to be held virtually on December 7 - 10, 2021.